Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

20.9%

31 terminated/withdrawn out of 148 trials

Success Rate

78.5%

-8.0% vs industry average

Late-Stage Pipeline

39%

57 trials in Phase 3/4

Results Transparency

56%

63 of 113 completed trials have results

Key Signals

63 with results26 terminated5 withdrawn

Enrollment Performance

Analytics

Phase 2

56(38.6%)

Phase 3

44(30.3%)

Phase 1

25(17.2%)

Phase 4

13(9.0%)

N/A

6(4.1%)

Early Phase 1

1(0.7%)

145Total

Phase 2(56)

Phase 3(44)

Phase 1(25)

Phase 4(13)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (148)

Showing 20 of 148 trials

NCT00373672Phase 4Completed

Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder

Role: collaborator

NCT00233675Phase 3Completed

Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder

Role: lead

NCT00129896Phase 1Completed

Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients

Role: collaborator

NCT00462943Phase 2Completed

Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML

Role: collaborator

NCT00375219Phase 2Completed

Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation

Role: collaborator

NCT01256905Not ApplicableWithdrawn

Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies

Role: collaborator

NCT01234766Phase 2Completed

Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma

Role: collaborator

NCT01470248Phase 2Completed

Study of Arsenic Trioxide in Small Cell Lung Cancer

Role: collaborator

NCT00469209Phase 1Completed

Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

Role: collaborator

NCT00052286Not ApplicableCompleted

Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer

Role: collaborator

NCT00901927Phase 2Terminated

Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma

Role: collaborator

NCT01222260Phase 2Completed

Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis

Role: collaborator

NCT00275067Phase 1Unknown

Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery

Role: collaborator

NCT01121536Phase 3Terminated

Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Role: lead

NCT00867503Phase 2Completed

Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer

Role: collaborator

NCT01272245Phase 2Completed

Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Role: collaborator

NCT01315873Phase 2Terminated

Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma

Role: collaborator

NCT01626352Phase 2Completed

Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy

Role: collaborator

NCT00825227Phase 2Terminated

Safety and Efficacy of Armodafinil for Fatigue Associated With Taxanes Alone or in Combination With Other Agents

Role: lead

NCT01042704Phase 1Completed

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

Role: collaborator